Skip to main content
LIRA@BC Law

Abstract

The Cancer Immunotherapy Pilot Program (also known as Patents 4 Patients) provides fast-track review to patent applications describing methods of treating cancer with immunotherapy, such as chimeric antigen receptor ("CAR")- T cell treatments. This article explores considerations for claiming CAR-T cell treatments, including court rulings and examiner guidelines on patentable subject matter in the life sciences, the Federal Circuit's decision in NantKwest, Inc. v. Lee in 2017, and pending applications and current litigation over CAR-T cell treatments.

Files

File nameDate UploadedVisibilityFile size
CHIMERIC_ANTIGEN_RECEPTOR_T_CELL.pdf
29 Nov 2022
Public
282 kB

Metrics

Metadata

  • Subject
    • Health Law and Policy

    • Science and Technology Law

  • Journal title
    • Boston College Intellectual Property and Technology Forum

  • Volume
    • 2018

  • Pagination
    • 1-33

  • Date submitted

    29 November 2022

  • Related URL